Souhaitez-vous accéder aux communiqués récents ?

Enrollment completed in ML-007C-MA’s Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004’s Phase 2 IRIS trial in autism...

WASHINGTON, May 14, 2026 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the findings of its third annual Hospital Operations Outlook Survey, which found that 92% of hospital...

Endless Frontier Labs at NYU Stern graduated its 2025–2026 cohort of 74 startups across 4 tracks — Digital Tech, Deep Tech, Life Sciences & Digital Health.

Kansas City, MO, May 12, 2026 (GLOBE NEWSWIRE) -- CRB Group, a global leader in sustainable engineering, architecture, construction, and consulting services, announced today that a CRB‑delivered...

Responding to a press report, Kneat confirms its Board of Directors has formed a special committee to review strategic alternatives.

SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor...

SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Accumulus Technologies today announced that the Accumulus Direct Connect for Veeva RIM (“Direct Connect”) is now live, marking the next milestone in...

FREMONT, CA, May 05, 2026 (GLOBE NEWSWIRE) -- iDox.ai announced the release of the Life Sciences and Healthcare Edition of its AI-powered privacy suite, designed to support organizations managing...

Nanomedicine expert joins Massachusetts Biomedical Initiatives (MBI) lab in Worcester to advance RNA therapeutics for musculoskeletal disease

Enrollment completed in ML-007C-MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2...